AptarGroup, Inc. (ATR) SEC Filings & Earnings Calls

Geopolitical risk: potential loss of control over Russian subsidiary; immaterial financial impact currently.

“Subsidiary represents <0.6% of net sales and operating income; company assessing options.”

Margin Compression from Product Mix

“Sales within our Pharma segment were negatively impacted by a mix of lower margin applications compared to the same period in 2025.” · word for word

Higher Interest Expense

“Interest expense increased approximately $5.2 million to $16.0 million in the second quarter of 2026 compared to $10.9 million for the same period of the prior year.” · word for word

Operational Ramp-Up Costs

“Adjusted EBITDA in the second quarter of 2026 decreased 6% to $29.8 million compared to $31.9 million reported in the same period of the prior year primarily due to higher operational costs associated with the ramp up of a new production line.” · word for word

Margin compression across all segments due to product mix, operational factors, and temporary headwinds.

“Adjusted EBITDA margin was 20.7% compared to 22.6% in the prior year... Pharma -180bps, Beauty -190bps, Closures -200bps”

Emergency medicine destocking continues to pressure Pharma sales, expected to abate by Q4.

“anticipated reduction in emergency medicine sales... headwind of emergency medicine destocking to abate by the fourth quarter” · word for word

Minimal risk from standard executive change with internal succession.

“Mr. Ackerman has taken on another leadership role within the Aptar Finance organization.” · word for word

Product mix shift pressuring margins

“This increase is mainly due to the lower sales of some higher margin Pharma products, and lower margins on our tooling sales compared to the first three months of 2025.” · word for word

Geopolitical and trade policy risk

“Geopolitical conditions, including trade disputes and acts of war or terrorism, could have a material adverse effect on our operations and financial results.” · word for word

Interest expense increase from debt refinancing

“Interest expense increased approximately $5.6 million to $16.9 million in the first three months of 2026 compared to $11.4 million during the same period in 2025.” · word for word

Emergency medicine destocking impacting Pharma prescription division; margin compression across segments due to mix and operational issues.

“first quarter results were impacted by emergency medicine destocking ... Adjusted EBITDA margin was 19.2% compared to 20.7%” · word for word

CEO transition introduces execution risk, but appears orderly with advance notice.

“CEO change effective September 1, 2026; employment agreement filed.”

Tariff cost pressure on margins

“Such tariffs and countermeasures have increased the cost of certain raw materials and components used in our packaging solutions, and have the potential to disrupt our global supply chain and create additional operational challenges.” · word for word

Beauty segment margin decline

“These factors, along with the pass through of higher tariff costs, led to our Adjusted EBITDA margin declining to 12.1% in 2025 compared to 13.0% in 2024.” · word for word

Geopolitical and trade disruption

“Geopolitical conditions, including trade disputes and acts of war or terrorism, could have a material adverse effect on our operations and financial results.” · word for word

Margin pressure across all segments due to product mix and higher costs

“Pharma margin down 330 bps, Beauty down 220 bps, Closures down 120 bps”

Destocking in emergency medicine expected to continue into Q1 2026

“Outlook: strong growth outside emergency medicine, which is going through destocking”

Increased debt load with change-of-control put option at 101%.

“Notes are unsecured; change of control repurchase event at 101% of principal”

Patent infringement litigation

“In May 2025, Nemera filed patent infringement actions against us in France and Germany relating to certain of our ophthalmic products.” · word for word

Antitrust lawsuit

“In September 2025, ARS Pharmaceuticals Operations, Inc. filed an antitrust lawsuit against us in the United States District Court for the Southern District of California, alleging violations of U.S. competition laws related to supply of certain components and are seeking injunctive relief and damages.” · word for word

Trade secret litigation

“In March 2025, we filed a lawsuit against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc. alleging that our confidential information and trade secrets were improperly disclosed and used.” · word for word

Tariff and trade restriction risk

“Significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures are taken by impacted foreign countries.” · word for word

Beauty and Closures segments face margin pressure from mix and lower tooling sales.

“Beauty adjusted EBITDA margin declined 120 bps to 12.1%; Closures margin declined 110 bps to 16.1%.”

Consumer healthcare demand softness in Europe (nasal/cold products) may persist.

“Consumer healthcare sales declined 11% due to softer demand in nasal and cold products. This was particularly evident in Europe.” · word for word

Currency headwinds impacted reported sales by 4% in Q3.

“Currency effects (4)% for total AptarGroup.”